Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.

Lamoth, F; Buclin, T; Csajka, C; Pascual, A; Calandra, T; Marchetti, O

Lamoth, F; Buclin, T; Csajka, C; Pascual, A; Calandra, T; Marchetti, O.

Affiliation

Lamoth F; Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland.

Antimicrob Agents Chemother ; 53(2): 785-7, 2009 Feb.

Article in En | MEDLINE | ID: mdl-19047655

Subject(s)

Anti-Bacterial Agents/administration & dosage; Anti-Bacterial Agents/therapeutic use; Hematologic Neoplasms/complications; Imipenem/administration & dosage; Imipenem/therapeutic use; Neutropenia/chemically induced; Neutropenia/complications; Adolescent; Adult; Aged; Anti-Bacterial Agents/pharmacokinetics; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; Female; Glomerular Filtration Rate; Guidelines as Topic; Hematologic Neoplasms/drug therapy; Humans; Imipenem/pharmacokinetics; Male; Middle Aged; Models, Biological; Young Adult

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Imipenem / Hematologic Neoplasms / Anti-Bacterial Agents / Neutropenia Type of study: Guideline Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Antimicrob Agents Chemother Year: 2009 Document type: Article Affiliation country: Switzerland Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google